Finally, human studies have shown impaired L-arginine transport in the failing myocardium and in hypertension, suggesting that the supplementation of L-arginine alone in the context of impaired transport may not be sufficient to improve the bioavailability of NOS-derived NO [116]. The gene discussed is NOS1; the disease is hypertensive disorder.